Fracturas vertebrales tras tratamiento hormonal en la menopausia: 20 años de seguimiento

Melton, 1995, How many women have osteoporosis now?, J Bone Miner Res, 10, 175, 10.1002/jbmr.5650100202 Johnell, 2005, Epidemiology of osteoporotic fractures, Osteoporos Int, 16, S3, 10.1007/s00198-004-1702-6 Pirro, 2010, High weight or body mass index increase the risk of vertebral fractures in postmenopausal osteoporotic women, J Bone Miner Metab, 28, 88, 10.1007/s00774-009-0108-0 Briggs, 2007, The vertebral fracture cascade in osteoporosis: A review of aetiopathogenesis, Osteoporos Int, 18, 575, 10.1007/s00198-006-0304-x De Villiers, 2012, The WHI: The effect of hormone replacement therapy on fracture prevention, Climacteric, 15, 263, 10.3109/13697137.2012.659975 Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Anderson, 2004, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial, JAMA, 291, 1701, 10.1001/jama.291.14.1701 2012, The 2012 hormone therapy position statement of: The North American Menopause Society, Menopause, 19, 257, 10.1097/gme.0b013e31824b970a LaCroix, 2011, Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial, JAMA, 305, 1305, 10.1001/jama.2011.382 Heiss, 2008, Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin, JAMA, 299, 1036, 10.1001/jama.299.9.1036 Stevenson, 2006, HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?, Hum Reprod, 21, 1668, 10.1093/humrep/del043 Studd, 2009, Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60, Climacteric, 12, 206, 10.1080/13697130902721873 Pines, 2007, IMS updated recommendations on postmenopausal hormone therapy, Climacteric, 10, 181, 10.1080/13697130701361657 Castelo-Branco, 1992, The effect of hormone replacement therapy on postmenopausal bone loss, Eur J Obstet Gynecol Reprod Biol, 44, 131, 10.1016/0028-2243(92)90058-7 Castelo-Branco, 1993, Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry, Maturitas, 16, 133, 10.1016/0378-5122(93)90057-O Genant, 1993, Vertebral fracture assessment using a semiquantitative technique, J Bone Miner Res, 8, 1137, 10.1002/jbmr.5650080915 Castelo-Branco, 1999, Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: Benefits to bone and analysis of factors associated with discontinuation, Menopause, 6, 307, 10.1097/00042192-199906040-00006 Calaf i Alsina, 1997, Benefits of hormone replacement therapy--overview and update, Int J Fertil Womens Med, 42, 329 1996, Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial, JAMA, 276, 1389, 10.1001/jama.1996.03540170033029 Prince, 1991, Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy, N Engl J Med, 325, 1189, 10.1056/NEJM199110243251701 Castelo-Branco, 1999, Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial, J Reprod Med, 44, 601 Torgerson, 2001, Hormone replacement therapy and prevention of vertebral fractures: A meta-analysis of randomised trials, BMC Musculoskelet Disord, 2, 7, 10.1186/1471-2474-2-7 Lindsay, 1980, Prevention of spinal osteoporosis in oophorectomised women, Lancet, 2, 1151, 10.1016/S0140-6736(80)92592-1 Lufkin, 1992, Treatment of postmenopausal osteoporosis with transdermal estrogen, Ann Intern Med, 117, 1, 10.7326/0003-4819-117-1-1 Banks, 2004, Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women, JAMA, 291, 2212, 10.1001/jama.291.18.2212 Greenspan, 2002, Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 137, 875, 10.7326/0003-4819-137-11-200212030-00008 Bea, 2011, Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative Hormone Trials, Menopause, 18, 44, 10.1097/gme.0b013e3181e3aab1 Wu, 2002, Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy, Clin Endocrinol (Oxf), 56, 703, 10.1046/j.1365-2265.2002.01534.x